Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients

• Status: Not yet recruiting
• Trial end date: 2027-12-30
• Target enrollment: 0
• Participant gender: Female

Summary

To evaluate if adjuvant concurrent chemoradiotherapy is associated with a recurrence-free survival benefit in comparison with radiotherapy alone in selected intermediate risk cervical cancer after radical surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ruijin Hospital

Criteria

Inclusion Criteria:

• • 18 Years to 80 Years

• Histologically proven cervical cancer, FIGO stage Ia2-IIb,and no previous chemotherapy and radiotherapy

• Accepted radical hysterectomy 3-4 weeks before

• Karnofsky score >70

• Postoperative pathology with one of the three risk factors criterials: (1) lympho-vascular space invasion(LVSI+) and deep 1/3 stromal invasion; (2 ) LVSI(+) and middle 1/3 stromal invasion, and tumor size≥4cm (3)Non-squamous cell carcinoma;

• Examination results showed no radiation or chemotherapy contraindication

• Willing to accept treatment

• Ability to comply with trial requirements

Exclusion Criteria:

• • Postoperative residual

• Postoperative recurrence or metastasis

• Pelvic lymph node metastasis

• parametrial invasion

• positive surgical margin

• Without lymph node dissection

• Postoperative pathology showed aortic lymph node metastasis

• Examination results showed radiotherapy contraindications

• No indications for radiotherapy